In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014–2019)

In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014–2019

(2023) Mark G. Wise et al.   Microbial Drug Resistance

Cefiderocol for the Treatment of Infections Due To Metallo-Beta-Lactamase-Producing Pathogens in the CREDIBLE-CR And APEKS-NP Phase 3 Randomized Studies

(2022) Jean-Francois Timsit et al.   CLINICAL INFECTIOUS DISEASES

NDM-35-Producing ST167 Escherichia coli Highly Resistant to β-Lactams Including Cefiderocol

(2022) Laurent Poirel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Nosocomial outbreak by NDM-1-producing Klebsiella pneumoniae highly resistant to cefiderocol, Florence, Italy, August 2021 to June 2022

(2022) Marco Coppi et al.   Eurosurveillance

Therapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales

(2021) Xing Tan et al.   Infection and Drug Resistance

Mobile Carbapenemase Genes in Pseudomonas aeruginosa

(2021) Eun-Jeong Yoon et al.   Frontiers in Microbiology

The urgent need for metallo-β-lactamase inhibitors: an unattended global threat

(2021) Maria F Mojica et al.   LANCET INFECTIOUS DISEASES

In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019

(2021) James A. Karlowsky et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftolozane-tazobactam and ceftazidime-avibactam activity against β-lactam-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Enterobacterales clinical isolates from U.S. medical centers

(2020) Elizabeth B. Hirsch et al.   Journal of Global Antimicrobial Resistance

Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the development pipeline

(2020) Sara E Boyd et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of cefiderocol, a siderophore-cephalosporin, against multidrug-resistant gram-negative bacteria

(2020) Shazad Mushtaq et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli

(2019) George G. Zhanel et al.   DRUGS

Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin

(2019) Takafumi Sato et al.   CLINICAL INFECTIOUS DISEASES

In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria

(2019) Yoshinori Yamano   CLINICAL INFECTIOUS DISEASES

Stability of cefiderocol against clinically significant broad-spectrum oxacillinases

(2018) Laurent Poirel et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases

(2016) Tsukasa Ito-Horiyama et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Interaction of Avibactam with Class B Metallo-β-Lactamases

(2016) Martine I. Abboud et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Correlation of β-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program

(2015) Patricia A. Bradford et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A review on colistin nephrotoxicity

(2015) Atefeh Ordooei Javan et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study

(2013) Mikhail V Edelstein et al.   LANCET INFECTIOUS DISEASES